Clinical trial · Interventional
The Effect of Cannabis in Pancreatic Cancer
The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer
NCT03245658CI-TRIAL-00072328withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Organization was changed. The staff was relocated.
Summary
Brief summary (as posted)
Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test the appetite stimulating effects of CBD in patients with pancreatic cancer in palliative treatment.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Appetite Loss | — | UNRESOLVED | — |
| Cachexia; Cancer | — | UNRESOLVED | — |
| Cannabis | — | UNRESOLVED | — |
| Morbidity | — | UNRESOLVED | — |
| Mortality | — | UNRESOLVED | — |
| Neoplasms Pancreatic | — | UNRESOLVED | — |
| Palliative Medicine | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| THC and CBD Mixture | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- THC and CBD Mixture
- description
- 32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks
- interventionNames
- Drug: THC and CBD Mixture
- type
- NO_INTERVENTION
- label
- Control
- description
- 32 patients with palliative pancreatic cancer, no experimental treatment,
Primary outcomes (1)
- measure
- Energy and protein intake
- timeFrame
- The outcome measure will be assessed at day 0 and at week 4
- description
- Dietary history (% of estimated needs - NRS 2002)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult, palliative pancreatic cancer diagnosis, weight loss \> 5%, understand and read Danish. Exclusion Criteria: * Regular use of cannabis, psychiatric disorders, alcohol abuse, life expectancy \< 6 months
References
Publications (12)
- RESULTPerras C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol. 2005 Sep;(72):1-4. PMID 16317825
- RESULTGartner S, Kruger J, Aghdassi AA, Steveling A, Simon P, Lerch MM, Mayerle J. Nutrition in Pancreatic Cancer: A Review. Gastrointest Tumors. 2016 May;2(4):195-202. doi: 10.1159/000442873. Epub 2016 Jan 8. PMID 27403414
- RESULTWare MA, Daeninck P, Maida V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag. 2008 Feb;4(1):99-107. doi: 10.2147/tcrm.s1132. PMID 18728826
- RESULTGrotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-60. doi: 10.2165/00003088-200342040-00003. PMID 12648025
- RESULTSlatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol. 2007 May;5(5 Suppl 3):1-9. PMID 17566383
- RESULTJohnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013 Aug;46(2):207-18. doi: 10.1016/j.jpainsymman.2012.07.014. Epub 2012 Nov 8. PMID 23141881
- RESULTJohnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010 Feb;39(2):167-79. doi: 10.1016/j.jpainsymman.2009.06.008. Epub 2009 Nov 5. PMID 19896326